This study was designed to compare the efficacy and safety of tislelizumab plus chemotherapy versus placebo plus chemotherapy as the first treatment (first-line) for adults diagnosed with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously untreated advanced/metastatic GC/GEJC |
Tislelizumab |
Placebo |
Primary Endpoint: OS in PD-L1+ (PD-L1 score ≥5%) and ITT population Key Secondary Endpoints: PFS, ORR, DoR, DCR, CBR, HRQoL, safety |
